Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:52a INSIDER TRADING ACTIVITY MYOKARDIA, : MYOK) – Insider Sold 32,988 shares ..
07/27 SANOFI : Pasteur Receives 2016 United Way Campaign Chair Award
07/27 SANOFI : Pasteur Ships First of its U.S. Influenza Vaccine Doses for 2017-2018 S..
07/26 SANOFI : Pasteur appoints new GM for Korea office
07/26SANOFI SA : half-yearly earnings release
07/26 SANOFI : Pasteur Korea elects new CEO
07/25 SANOFI : Rich fly to Singapore for lifesaving dengue vaccine; poor helpless due ..
07/23 SANOFI : Judicial Panel on Multidistrict Litigation Issues Order on Taxotere
07/22 SANOFI : Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Tre..
07/22 SANOFI : MSDs Lantus biosimilar given conditional FDA approval
More news
News from SeekingAlpha
07/27 THE 'BEST BALANCE SHEETS' PORTFOLIO : LabCorp
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
07/24 Boulder Growth & Income Fund Is At Least 5% Overvalued And A Poor Long-Term H..
07/23 Tracking Ken Fisher'S Fisher Asset Management Portfolio - Q2 2017 Update
07/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 23, 2017
Financials (€)
Sales 2017 36 412 M
EBIT 2017 9 526 M
Net income 2017 7 919 M
Debt 2017 4 789 M
Yield 2017 3,71%
P/E ratio 2017 13,30
P/E ratio 2018 17,13
EV / Sales 2017 2,98x
EV / Sales 2018 2,86x
Capitalization 103 647 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 €
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.91%121 857
JOHNSON & JOHNSON13.66%352 757
NOVARTIS9.04%222 032
ROCHE HOLDING LTD.4.21%220 038
PFIZER1.26%195 864
MERCK AND COMPANY8.19%169 033